Crescendo Biologics Ltd., a clinical stage immuno-oncology company developing targeted T cell enhancing therapeutics, plans to augment the ongoing Phase 1b clinical trial of CB307 through the addition of a new pembrolizumab (anti-PD-1) combination expansion cohort. Additional financing of $32 million has been secured to fund the combination expansion arm of the adaptive clinical protocol, with support of all major existing shareholders, including Sofinnova Partners, Andera Partners, IP Group ...